Evidence map›Paper›PMID 42059468›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer.

Beau R Brummel, Sofia Kokkaliari, Qiwen Gao, Jinjing Chen, Larissa Costa de Almeida, Srinivasarao Tenneti, Derek A Leas, Eli Levit, Lewis S Alexander, Khalil A Abboud and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Beau R BrummelDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Sofia KokkaliariDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Qiwen GaoDepartment of Pharmaceutical & Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0000-0001-5043-9669
Jinjing ChenDepartment of Molecular Medicine, Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.
Larissa Costa de AlmeidaDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Srinivasarao TennetiDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Derek A LeasDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Eli LevitDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Lewis S AlexanderDepartment of Molecular Medicine, Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.
Khalil A AbboudDepartment of Chemistry, University of Florida, Gainesville, Florida, USA.
Pingrong WeiDepartment of Chemistry, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia, USA.
Michael D CameronDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.ORCID https://orcid.org/0000-0003-3154-4775
James R RoccaDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Ranjala RatnayakeDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-5980-2070
Donna D ZhangDepartment of Molecular Medicine, Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida, USA.ORCID https://orcid.org/0000-0002-8972-697X
Hendrik LueschDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-4091-7492
Robert W HuigensDepartment of Medicinal Chemistry and Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0003-3811-2721

Funding

Comprehensive Training Program in Oral BiologyT90DE021990 · NIDCR · UNIVERSITY OF FLORIDA · PI Jose A Lemos · 2011 to 2026
$8.2M
NRF Transcription Factors in Environmental Stress and Disease InterventionR35ES031575 · NIEHS · UNIVERSITY OF FLORIDA · PI Donna D Zhang · 2020 to 2026
$7.1M
Novel Targeted Anticancer Agents from Marine CyanobacteriaR01CA172310 · NCI · UNIVERSITY OF FLORIDA · PI HENDRIK LUESCH · 2013 to 2026
$5.8M
Team-based Interdisciplinary Cancer Research Training ProgramT32CA257923 · NCI · UNIVERSITY OF FLORIDA · PI SIEMANN, DIETMAR W · 2021 to 2025
$1.2M
Indole Alkaloids and Halogenated Phenazines: Platforms for DiscoveryR35GM153272 · NIGMS · UNIVERSITY OF GEORGIA · PI Robert William Huigens · 2024 to 2026
$1.1M
Acquisition of a Q Exactive HF Hybrid Quadrupole-OrbitrapS10OD021758 · OD · UNIVERSITY OF FLORIDA · PI BASSO, KARI B · 2017 to 2017
$600k
American Cancer Society RSG-18-013-01Debbie and Sylvia DeSantis Chair ProfessorshipNational Science Foundation CHE-1828064National Science Foundation Cooperative DMR-2128556NCI NIH HHS R01 CA172310NCI NIH HHS R01CA172310NCI NIH HHS T32 CA257923NCI NIH HHS T32-CA257923NIDCR NIH HHS T90 DE021990NIDCR NIH HHS T90DE021990NIEHS NIH HHS R35 ES031575NIGMS NIH HHS R35ES031575NIGMS NIH HHS R35 GM153272NIGMS NIH HHS R35GM153272NIH HHS S10 OD021758NIH HHS S10 OD021758-01A1University of Florida Interdisciplinary Center for Biotechnology Research
6 · The paper itself

Abstract

We discovered a thiolate-reactive α,α-gem-dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti-inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. Our findings originated from new compounds accessed through aza-oxyallyl cation-mediated [3+2]-cycloadditions of ajmalicine and inspired indoles. RNA-seq and Ingenuity Pathway Analysis illuminated detailed transcriptional profiles of α,α-gem-dibromo lactams to show activation of the antioxidant Keap1/Nrf2 pathway and suppressed NF-κB-mediated inflammatory signaling. We demonstrated the importance of the α,α-gem-dibromo lactam, as the corresponding α,α-gem-dichloro lactam is unable to activate the Nrf2 pathway. Chemical reactions with cysteine-containing compounds suggested α,α-gem-dibromo lactams react with cysteine residues to transfer electrophilic bromine to target molecules, linking unique chemistry to our biological findings. In contrast to electrophiles that activate the canonical Nrf2 pathway by covalently targeting C151 of Keap1, the α,α-gem-dibromo lactams function in a C151-independent manner, indicating a distinct selectivity and consequently mode of action. Pharmacological profiling of several α,α-gem-dibromo lactams compared with ajmalicine against adrenergic receptors revealed substantial differences, indicating tunability and novel pharmacology. Future investigations aim to explore the fundamental activities of the dibromo lactam warhead related to human disease. Installation of this warhead into various molecular scaffolds may be a generalizable method to create cystein-reactive electrophiles.

Indexed as

Biological ProductsLactamsNF-E2-Related Factor 2AnimalsAnti-Inflammatory AgentsHumansKelch-Like ECH-Associated Protein 1Signal TransductionAnti-Inflammatory AgentsBiological ProductsKelch-Like ECH-Associated Protein 1LactamsNFE2L2 protein, humanNF-E2-Related Factor 2antioxidant response elementantioxidant response element activating agentscomplexity‐to‐diversityindole alkaloidsmolecular warhead

Identifiers

PMID42059468
PMCPMC13334971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.